Tiziana Life Sciences Ltd

This early study tests a nasal spray called foralumab in 5 adults with multiple system atrophy (MSA), a rare brain disease that gets worse over time. The goal is to see if the drug can reduce harmful brain inflammation and slow down symptoms like movement problems. Researchers wi…

This phase 2a trial tests a nasal spray called foralumab in 54 people with non-active secondary progressive multiple sclerosis (SPMS). The spray contains an antibody that aims to calm overactive immune cells in the brain. Participants will receive either a low dose, a high dose, …